BPH Global Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms. Basic parameters: from 18 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, Canada, Chile, China, Cyprus +14
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia
Overview
Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.
Detailed description
Due to a growing and aging population, cases of benign prostatic hyperplasia (BPH) have been on a steady rise. Studies show that by age 80, 90% of men experience BPH. (Garraway, Lee, Collins, 1991) Thus, treatment of BPH is one of the most performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been somewhat standardized. The purpose of this study is to create an ongoing prospective registry to record demographic data and clinical outcomes after medical therapy or different surgical interventions for BPH. The specific aims of the registry are to analyze demographic patterns and baseline characteristics of men undergoing surgical and medical treatments for BPH, to assess global practice patterns for various surgical and medical treatments of BPH, and to assess key outcomes for uni- and multi-modal treatments of BPH.
The ongoing global registry will provide important baseline data, functional outcomes, and complications following medical and/or surgical intervention for men with symptomatic BPH. The intention of the registry is to provide real world usage data that may be used for future investigations. It will allow providers to identify areas of interest, areas of unusually low usage or areas of unusual preference on a global scale. It will also shed light on global preferences for unimodal or multimodal approaches to treatments.
The registry has been developed using novel database technology, providing an easy-to-use user interface, which enables future creation of patient portals and Electronic Medical Record (EMR) integration.
As this is not an experimental setting, there will be no interventions made on behalf of the registry.
This is a prospective longitudinal ongoing registry. The study will include medical records of all men ≥18 years old who have a primary diagnosis of BPH with Lower Urinary Tract Symptoms (LUTS) that are prescribed BPH medications, or a surgical intervention. Data extraction includes baseline data, peri-operative data, and follow-up data. Baseline data includes validated patient reported outcome tools, including International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire - Ejaculatory Dysfunction (MSHQ-EjD), as well as Quality of Life (QoL), maximum flow rate (Qmax), Post-void residual (PVR), Prostate Specific Antigen (PSA), and Testosterone. Complications such as Bleeding, Urinary Tract Infection (UTI), Incontinence, Stricture, Retrograde ejaculation, and Erectile Dysfunction (ED) are also tracked from Baseline through Follow-up.
The registry will run for 3 years with no end point for follow-up. For three years, various research studies will be formulated, and the results will be published. The possibility of extending the study for continued follow-up will be evaluated.
A built-in quality control using data validation during the input process decreases the chance that invalid data will be entered or that datapoints will be omitted. Periodic audits will be performed to verify accuracy of source data by our audit committee based on our audit committee guidelines.
Records and cases of all men with a primary diagnosis of BPH with LUTS that are prescribed BPH medications, or a surgical intervention will be identified and included in the registry. All data is hashed (i.e., protected from decryption) except for a medical record number (MRN), which will be used to add follow-up data to the patient's record. This number is encrypted and linked to the hashed and randomly generated institution code. For security purposes, biographical information is not saved on the registry.
The registry provides secure access to registered users using a web browser. Registrations are site-specific, which means that users can only access the data that is specific to their own site. The registry application and databases are hosted on secure, encrypted servers behind a firewall. They can only be accessed by registered users via a specific port.
Primary outcome measures
- International Prostate Symptom Score (IPSS) [Time frame: 36 months]
- Quality of Life (QoL) [Time frame: 36 months]
- Post-Void Residual (PVR) [Time frame: 36 months]
- Complications (including incontinence) [Time frame: 36 months]
Secondary outcome measures (4)
- Prostate Volume (cc) [Time frame: 36 months]
- Qmax [Time frame: 36 months]
- Male Sexual Health Questionnaire Ejaculatory Dysfunction (MSHQ-EjD) [Time frame: 36 months]
- Sexual Health Inventory for Men (SHIM) [Time frame: 36 months]
Eligibility criteria
Inclusion criteria
- Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention
Exclusion criteria
- Non-symptomatic BPH
- No treatment prescribed for BPH
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Canada · 3 centers
- Toronto Western Hospital, University Health Network — Toronto
- McGill University Health Centre — Montreal
- University of Montreal Hospital Center — Montreal
Chile · 2 centers
- Hospital Dr. Juan Morey La Unión — La Unión
- Hospital del Trabajador — Santiago
Italy · 2 centers
- Azienda Ospedaliero-Universitaria Careggi — Florence
- Sapienza University of Rome, Division of Urology, Ospedale Sant'Andrea — Rome
Nigeria · 2 centers
- Benue State University Teaching Hospital, Department of Surgery — Makurdi
- Ahmadu Bello University Teaching Hospital — Zaria
Pakistan · 2 centers
- Institute of Kidney Diseases Peshawar — Peshawar
- Lady Reading Hospital — Peshawar
United Kingdom · 2 centers
- Imperial College Healthcare NHS Trust — London
- Southend University Hospital — Southend-on-Sea
United States · 1 center
- Keck Medicine of USC — Los Angeles
China · 1 center
- The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou
Cyprus · 1 center
- University of Cyprus — Nicosia
Hong Kong · 1 center
- The Chinese University of Hong Kong — Hong Kong
Iran · 1 center
- Shariati Hospital — Tehran
Iraq · 1 center
- University of Basrah — Basra
Lebanon · 1 center
- American University of Beirut — Beirut
Malaysia · 1 center
- Universiti Malaya — Kuala Lumpur
Mali · 1 center
- Kati University Hospital — Kati
Mexico · 1 center
- Centro Medico Nacional Siglo XXI — Mexico City
Qatar · 1 center
- Hamad Medical Corporation Qatar — Doha
South Korea · 1 center
- Seoul National University Bundang Hospital — Seongnam
Turkey (Türkiye) · 1 center
- Istanbul Medipol University — Istanbul
Identifiers
NCT: NCT05543200 · uCARE-2022-001